Hormonal

Pfizer will talk to regulators about pivotal study designs in cachexia following promising ponsegromab Phase II data, with results from a separate study in heart failure also coming soon.

The company said the results did not meet the threshold for continued capital investment, giving a boost to Spruce Biosciences and its competing congenital adrenal hyperplasia program.

The follow-on Cushing’s product relacorilant has hit in Phase III, and is forecast to lead the market – eventually.